Researchers at Glasgow University find parents and caregivers of people with Dravet Syndrome need better support.

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Neurvati Neurosciences, a clinical-stage biotechnology company dedicated to bringing a new generation of therapies to people affected by neurological and psychiatric disorders, and GRIN Therapeutics, ...

CBD oil's popularity surges across wellness and pharmaceutical sectors, lauded for potential benefits like pain and anxiety ...

Paige Figi — mom to Charlotte Figi, the child whose story captivated the nation as CBD helped her seizure disorder — tells ...

Paige Figi once came under fire for the medical decisions she made as a mom. Now, she tells PEOPLE about blocking out the ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

The link between brain health and climate disruption was recently highlighted in a 16-minute mini-documentary shared online ...

NICE estimates that there are around 1,400 people who will now be eligible for treatment with Fintepla, which was previously backed by NICE for Dravet syndrome, another severe epilepsy disorder ...

Story Feb. 13 - Encoded Therapeutics: The gene therapy biotech is laying off 29% of staffers as it focuses resources toward its Dravet syndrome program. Most of the affected roles will be in ...

Conducted by researchers at the University of Glasgow in partnership with Dravet Syndrome UK, the resulting study, published ...